Search Results - Markus Joerger

New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development by Kira-Lee Koster, Jens Huober, Markus Joerger

Connect to this object online.

Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti‐cachexia by David Blum, Caroline Hertler, Rolf Oberholzer, Susanne deWolf‐Linder, Markus Joerger, Christoph Driessen, Florian Strasser

Connect to this object online.

A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients by Francis Williams Ojara, Andrea Henrich, Nicolas Frances, Yomna M. Nassar, Wilhelm Huisinga, Niklas Hartung, Kimberly Geiger, Stefan Holdenrieder, Markus Joerger, Charlotte Kloft

Connect to this object online.

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen by Lena Klopp-Schulze, Anna Mueller-Schoell, Anna Mueller-Schoell, Patrick Neven, Stijn L. W. Koolen, Ron H. J. Mathijssen, Markus Joerger, Charlotte Kloft

Connect to this object online.

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies by Anna Mueller-Schoell, Lena Klopp-Schulze, Robin Michelet, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus, Charlotte Kloft

Connect to this object online.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis by Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema

Connect to this object online.